Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer.
Questions
1. What are the major unmet needs in the treatment of triple-negative breast cancer? (0:06)
2. What is the rationale for the combined use of cisplatin and veliparib in metastatic triple-negative breast cancer? (0:49)
3. Early studies of combined PARP inhibitors/chemotherapy have been challenging due to exacerbation of myelosuppression. How does veliparib overcome this? (2:20)
4. Could you tell us a little about the SWOG S1416 study and its efficacy and safety findings? (3:20)
5. What are the next steps for this combined therapy? (5:10)
Speaker disclosure: Priyanka Sharma has no financial or non-financial relationships or activities to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
